RecruitingNCT06307938

Circulating Tumor DNA in Patients Summoned for Colonoscopy; - a Liquid Biopsy for Detection, Characterization, Individualized Treatment and Follow-up of Colorectal Cancer

Sponsor

Helse Nord-Trøndelag HF

Enrollment

3,000 participants

Start Date

Mar 10, 2025

Study Type

OBSERVATIONAL

Conditions

Colorectal, Cancer Colorectal Adenoma

Summary

CoLiQ is a clinical study designed to evaluate the clinical usefulness of circulating tumor DNA (ctDNA) markers found in blood, as a liquid biopsy for diagnosis, prognosis and follow-up of colorectal cancer. The main questions it aims to answer are: 1) Can a panel of ctDNA markers identify CRC patients among the other patients summoned for colonoscopy? and 2) Does the type, number and level of ctDNA markers vary with the subtype and clinical course of CRC? Participants will be asked to answer a questionnaire and give a blood sample at inclusion. In addition, patients with CRC will be asked to give an extra test tube at their routine treatment and follow-up blood sampling.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study collects blood samples (liquid biopsies) from people scheduled for colonoscopy to test whether circulating tumor DNA — tiny fragments of cancer DNA floating in the bloodstream — can detect, characterize, and help monitor colorectal cancer and precancerous polyps. **You may be eligible if...** - You are 18 years or older - You are already scheduled to have a colonoscopy - You can understand and sign written informed consent **You may NOT be eligible if...** - You are under 18 years old - You are unable to understand or sign informed consent - You are unlikely to complete all follow-up visits as determined by the study investigator Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.